Bank of New York Mellon Corp Makes New $149.28 Million Investment in Natera, Inc. $NTRA

Key Points

• Bank of New York Mellon acquired 549,927 Natera shares worth approximately $149.3 million, giving it a 0.38% stake. Institutional investors collectively own 99.90% of Natera’s stock.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $319.38. Citigroup and Stephens recently raised their price targets to $365 and $350, respectively.
• Natera’s latest quarterly revenue rose 37.7% year over year to $752.75 million, exceeding estimates, while adjusted losses of $0.47 per share were slightly better than expected. The stock opened at $332.03, near its 12-month high of $333.56.

Bank of New York Mellon Corp acquired a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 549,927 shares of the medical research company's stock, valued at approximately $149,278,000. Bank of New York Mellon Corp owned about 0.38% of Natera at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NTRA. JPMorgan Chase & Co. increased its position in shares of Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. State Street Corp grew its position in Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company's stock worth $545,624,000 after acquiring an additional 72,087 shares during the last quarter. Coatue Management LLC raised its holdings in shares of Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock valued at $603,270,000 after buying an additional 2,463,008 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Natera by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company's stock valued at $596,078,000 after buying an additional 11,689 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on NTRA shares. Zacks Research raised Natera from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 12th. UBS Group set a $260.00 price target on shares of Natera in a report on Wednesday, June 24th. Citigroup upped their price objective on shares of Natera from $315.00 to $365.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. Stephens boosted their target price on Natera from $305.00 to $350.00 and gave the company an "overweight" rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Natera in a report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $319.38.

Insider Activity

In other news, insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the transaction, the insider owned 129,019 shares of the company's stock, valued at $34,264,866.02. This trade represents a 2.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roelof Botha sold 78,000 shares of the firm's stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the completion of the sale, the director owned 1,076,198 shares of the company's stock, valued at $237,097,181.38. This trade represents a 6.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 181,045 shares of company stock worth $41,330,968. Corporate insiders own 5.05% of the company's stock.

Natera Price Performance

NASDAQ NTRA opened at $332.03 on Monday. The firm's 50 day moving average is $274.24 and its 200-day moving average is $229.38. The company has a market capitalization of $47.86 billion, a PE ratio of -244.14 and a beta of 1.51. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $333.56.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm's revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.74) earnings per share. As a group, sell-side analysts expect that Natera, Inc. will post -1.02 EPS for the current year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source